These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37795027)

  • 21. Delivering a New Future for People With Cystic Fibrosis.
    Burgener EB; Cornfield DN
    Pediatrics; 2023 Oct; 152(4):. PubMed ID: 37671451
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
    Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
    Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy.
    Hisert KB; Birket SE; Clancy JP; Downey DG; Engelhardt JF; Fajac I; Gray RD; Lachowicz-Scroggins ME; Mayer-Hamblett N; Thibodeau P; Tuggle KL; Wainwright CE; De Boeck K
    Lancet Respir Med; 2023 Oct; 11(10):916-931. PubMed ID: 37699420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient perspectives following initiation of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis and advanced lung disease.
    Martin C; Burnet E; Ronayette-Preira A; de Carli P; Martin J; Delmas L; Prieur B; Burgel PR
    Respir Med Res; 2021 Nov; 80():100829. PubMed ID: 34091202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-life impact of highly effective CFTR modulator therapy in children with cystic fibrosis.
    Olivier M; Kavvalou A; Welsner M; Hirtz R; Straßburg S; Sutharsan S; Stehling F; Steindor M
    Front Pharmacol; 2023; 14():1176815. PubMed ID: 37229253
    [No Abstract]   [Full Text] [Related]  

  • 26. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
    Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
    N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy.
    Ridley K; Condren M
    J Pediatr Pharmacol Ther; 2020; 25(3):192-197. PubMed ID: 32265602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isotope dilution LC-MS/MS quantification of the cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor, lumacaftor, tezacaftor, elexacaftor, and their major metabolites in human serum.
    Habler K; Kalla AS; Rychlik M; Bruegel M; Teupser D; Nährig S; Vogeser M; Paal M
    Clin Chem Lab Med; 2022 Jan; 60(1):82-91. PubMed ID: 34668357
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
    Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
    Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenged Urine Bicarbonate Excretion as a Measure of Cystic Fibrosis Transmembrane Conductance Regulator Function in Cystic Fibrosis.
    Berg P; Sorensen MV; Rousing AQ; Vebert Olesen H; Jensen-Fangel S; Jeppesen M; Leipziger J
    Ann Intern Med; 2022 Nov; 175(11):1543-1551. PubMed ID: 36315944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis.
    Westhölter D; Schumacher F; Wülfinghoff N; Sutharsan S; Strassburg S; Kleuser B; Horn PA; Reuter S; Gulbins E; Taube C; Welsner M
    J Cyst Fibros; 2022 Jul; 21(4):713-720. PubMed ID: 35168870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lived experiences of people with cystic fibrosis that were not eligible for elexacaftor-tezacaftor-ivacaftor (ETI): A qualitative study.
    Milo F; Ciciriello F; Alghisi F; Tabarini P
    J Cyst Fibros; 2023 May; 22(3):414-419. PubMed ID: 36549989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro.
    Shaughnessy CA; Zeitlin PL; Bratcher PE
    J Cyst Fibros; 2022 Jul; 21(4):637-643. PubMed ID: 35248469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review.
    Kapouni N; Moustaki M; Douros K; Loukou I
    Children (Basel); 2023 Mar; 10(3):. PubMed ID: 36980112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Update on Clinical Outcomes of Highly Effective Modulator Therapy.
    Gifford AH; Taylor-Cousar JL; Davies JC; McNally P
    Clin Chest Med; 2022 Dec; 43(4):677-695. PubMed ID: 36344074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Effects of Elexacaftor, Tezacaftor, and Ivacaftor (ETI) on Blood Glucose in Patients With Cystic Fibrosis: A Systematic Review.
    Salazar-Barragan M; Taub DR
    Cureus; 2023 Jul; 15(7):e41697. PubMed ID: 37575762
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precision Medicine Based on CFTR Genotype for People with Cystic Fibrosis.
    Haq I; Almulhem M; Soars S; Poulton D; Brodlie M
    Pharmgenomics Pers Med; 2022; 15():91-104. PubMed ID: 35153502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful pregnancy in a cystic fibrosis patient with a severe impairment of lung function receiving Elexacaftor-Tezacaftor-Ivacaftor.
    Balmpouzis Z; Faure van Rossum A; Baud D; Panchaud A; Mitropoulou G; Mazza Stalder J; Koutsokera A
    Respir Med Case Rep; 2022; 40():101776. PubMed ID: 36386288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pseudomonas aeruginosa infection, but not mono or dual-combination CFTR modulator therapy affects circulating regulatory T cells in an adult population with cystic fibrosis.
    Westhölter D; Beckert H; Straßburg S; Welsner M; Sutharsan S; Taube C; Reuter S
    J Cyst Fibros; 2021 Nov; 20(6):1072-1079. PubMed ID: 34030985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elexacaftor/tezacaftor/ivacaftor projected survival and long-term health outcomes in people with cystic fibrosis homozygous for F508del.
    Lopez A; Daly C; Vega-Hernandez G; MacGregor G; Rubin JL
    J Cyst Fibros; 2023 Jul; 22(4):607-614. PubMed ID: 36849331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.